| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-01-22 | Cellaviva (Sweden) | nomination |
Regenerative medicine | Nomination | ||
| 2016-01-21 | Pfizer (USA - NY) Philogen (Italy) | empowered antibodies including antibody drug conjugates | R&D licensing |
Exercise of an option agreement | ||
| 2016-01-21 | The Lead Discovery Center (LDC) (Germany) Roche (Switzerland) | R&D collaboration |
R&D agreement | |||
| 2016-01-21 | Affimed (Germany) | nomination |
Nomination | |||
| 2016-01-20 | Saniona (Denmark) Upsher-Smith (USA - MN) Proximagen (UK) | small molecule therapeutics for neurological disorders, using ion channels and related technology platforms | neurological diseases | R&D collaboration development |
Neurological diseases | R&D agreement |
| 2016-01-20 | CEVEC Pharmaceuticals (Germany) Beckman Research Institute of City of Hope (USA - CA) | CAP®GT technology for the production of lentiviral and adenoviral vectors | licensing collaboration |
Technology - Services | Licensing agreement | |
| 2016-01-20 | Argos Therapeutics (USA - NC) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-01-19 | J&J (USA - NJ) | restructuring |
Medical devices | Restructuring | ||
| 2016-01-19 | Novozymes (Denmark) | Albumedix | restructuring |
Technology - Services | Restructuring | |
| 2016-01-19 | AmpliPhi BioSciences (USA - VA) | nomination |
Infectious diseases | Nomination | ||
| 2016-01-19 | Immunovia (Sweden) the University of Liverpool (UK) | IMMray™ PanCan-d (blood based test for early detection of pancreatic cancer) | pancreatic cancer | collaboration |
Cancer - Oncology - Diagnostic | Collaboration agreement |
| 2016-01-19 | Akcea Therapeutics (USA - CA) | nomination |
Cardiovascular diseases - Metabolic diseases | Nomination | ||
| 2016-01-19 | Merck KGaA (Germany) | nomination |
Nomination | |||
| 2016-01-19 | Cellectis (France) CellforCure (France) | UCART123 | production manufacturing |
Technology - Services | Production agreement | |
| 2016-01-18 | Silence Therapeutics (UK) | nomination |
Nomination | |||
| 2016-01-18 | Centauri Therapeutics (UK) | nomination |
Infectious diseases | Nomination | ||
| 2016-01-18 | Centauri Therapeutics (UK) Altermune Technologies (USA - CA) | Alphamer technology | infectious diseases | product acquisition |
Technology - Services - Infectious diseases | Product acquisition |
| 2016-01-18 | Santhera Pharmaceuticals (Switzerland) Ewopharma (Switzerland) | Raxone® (idebenone) | Leber\'s hereditary optic neuropathy (LHON) | distribution supply |
Rare diseases - Genetic diseases - Ophtalmological diseases | Distribution agreement |
| 2016-01-18 | Silence Therapeutics (UK) | nomination resignation |
Nomination | |||
| 2016-01-15 | UCB (Belgium) | nomination |
Bone diseases | Nomination |
